Business
Cumberland Pharmaceuticals Releases Inaugural Report On Its Environmental, Social And Governance (ESG) Activities
Includes Details About Company's Community Involvement, Ethical Marketing & Drug Safety NASHVILLE, Tenn., April 28, 2020 /PRNewswire/ -- Cumberland
About this update from Cumberland Pharmaceuticals Inc.
[{"type":"text","content":"Includes Details About Company's Community Involvement, Ethical Marketing & Drug Safety\n\n\nNASHVILLE, Tenn., April 28, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today released its first Sustainability Report. This report describes the company's activities pertaining to Environmental, Social and Governance (ESG) matters, otherwise known as corporate sustainability. It includes details about Cumberland's community involvement, ethical marketing and drug safety.\n\n \n \n \n \n \n \n\n \nCumberland's board has appointed Caroline R. Young as the company's first ESG board director. She is the former president of the Nashville Health Care Council and founding executive director of Life Science Tennessee. Currently, Young is executive director of NashvilleHealth, an initiative focused on improving the health of citizens in the metropolitan Nashville, Tennessee area.\n\"As the largest biopharmaceutical company founded and headquartered in the mid-South, Cumberland is committed to sustainability and transparency,\" Young said. \"This inaugural ESG report represents a milestone for Cumberland and will build upon the foundation of corporate responsibility the company has established over the years. We look forward to sharing updates as we fulfill this important initiative.\"\nThe sustainability reports notes that, during 2019, Cumberland provided nearly 4 million patient doses of its products, safely disposed of over 9,700 pounds of expired and damaged products and had no product recalls. The company also had no product listings on the FDA's Safety Alerts Database and no products identified in the FDA Adverse Event Reporting System during 2019.\n\"The ESG policies and practices we've built into our daily operations are central to our commitment to fulfilling our mission of delivering high-quality medicines, while addressing the interests of our shareholders, employees, partners and community,\" said A.J. Kazimi, chief executive officer of Cumberland Pharmaceuticals. \nFor more information on how Cumberland is addressing topics of importance to its employees, investors and the communities it serves, please view Cumberland's 2019 Sustainability Report at www.cumberlandpharma.com on the Corporate Governance section's Investor Relations page.\nAbout Cumberland Pharmaceuticals\nCu...